Longevity
PNC-27 Dosage Protocol
A chimeric p53-penetratin peptide studied for selective cancer cell necrosis via surface HDM-2 targeting. Complete dosing guide and peer-reviewed references.
Last reviewed March 2025 · 2 cited sources
Reconstitution
Add 3.0 mL BAC water → 10 mg/mL
Daily dose range
Research protocol-dependent (titrated)
Unit math (U-100 syringe)
1 unit = 0.01 mL ≈ 100 mcg
Storage (lyophilized)
Freeze at −4 °F · Reconstituted: 36–46 °F · Use within 28 days
Dosing & Reconstitution Guide
The protocol below uses a 3.0 mL reconstitution volume to keep injection units comfortably above 10 on a standard U-100 insulin syringe, reducing measurement error. Doses are titrated as shown below.
| Phase |
Daily dose |
U-100 units |
Injection volume |
| Research | Protocol-dependent | IV dosing | Variable |
Route: IV · Frequency: IV, protocol-dependent · Cycle: Research protocols
Reconstitution steps
01
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
02
Inject the water slowly down the interior wall of the peptide vial -never directly onto the powder -to prevent foaming and denaturation.
03
Swirl or roll gently until fully dissolved. Do not shake. The lyophilized powder should dissolve completely within 30–60 seconds.
04
Label the vial with the reconstitution date and concentration (10 mg/mL). Refrigerate at 36–46 °F, protected from light. Use within 28 days.
Research use only. This protocol is derived from published preclinical and early-phase clinical literature. PNC-27 is not FDA-approved for human use. This information is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before beginning any peptide protocol.
Supplies Needed
Estimates below assume the titration schedule listed above.
PNC-27 vials (30 mg each)
Per cycleAs needed per titration
U-100 insulin syringes
8 weeks56 syringes
12 weeks84 syringes
16 weeks112 syringes
Bacteriostatic water (10 mL bottles)
Alcohol swabs (100-count boxes)
8 weeks2 boxes (~112 swabs)
12 weeks2 boxes (~168 swabs)
16 weeks3 boxes (~224 swabs)
Storage Instructions
Lyophilized (dry powder)
−4 °F
Store frozen in dry, dark conditions. Minimize humidity exposure. Stable for 12–24 months when properly stored.
Reconstituted (in solution)
36–46 °F
Refrigerate after reconstitution. Use within 28 days. Do not refreeze reconstituted solution -freeze-thaw cycles degrade peptide integrity.
Allow refrigerated vials to reach room temperature before opening to minimize condensation uptake. Always inspect for cloudiness or particulates before use -discard if present.
Looking for research-grade peptides? Pacific Edge Labs carries a growing catalog of high-purity compounds with third-party lab results published on each product page.
Why Pacific Edge Labs
- High-purity compounds with third-party lab results available on the website
- Consistent quality control with ISO-aligned handling and documentation
- Fast, discreet shipping with proper handling and packaging
Browse Pacific Edge Labs →
PNC-27 is not currently in the PEL catalog -check back for availability.
How PNC-27 Works
PNC-27 is a chimeric peptide combining two functional domains: residues 12–26 of the p53 tumor suppressor protein fused to a penetratin transmembrane translocation sequence. The peptide exploits a unique feature of cancer cells -the overexpression of HDM-2 (human double minute 2) on the cell surface, which is not found on normal cells.[1]
When PNC-27 binds surface HDM-2, the penetratin domain inserts into the cancer cell membrane, forming pores that lead to rapid necrotic cell death. Normal cells, which express HDM-2 only intracellularly, are spared. In vitro studies have demonstrated activity against pancreatic cancer, breast cancer, and leukemia cell lines.[2]
Observed Effects & Side Effect Profile
The following observations are derived from preclinical literature and limited early-phase human data. They do not constitute clinical claims.
Reported benefits (research literature)
- Selectively targets cancer cells expressing surface HDM-2 -spares normal cells
- Active against multiple cancer cell lines in vitro (pancreatic, breast, leukemia)
- Novel mechanism distinct from traditional chemotherapy
- Rapid necrotic action -does not depend on apoptotic pathway integrity
Known limitations & side effects
- No human clinical trial data available
- IV administration required -research protocol-dependent dosing
- In vitro activity may not translate to in vivo efficacy
- Very early-stage research compound
- Potential systemic toxicity at therapeutic concentrations unknown
Lifestyle Considerations
While the following suggestions are not protocol requirements, research on tissue repair and peptide efficacy consistently highlights these as factors that influence outcomes:
01
Protein intake. Collagen synthesis and tissue remodeling require adequate dietary protein. Research generally supports 1.6–2.2 g/kg/day during active recovery periods.
02
Sleep. The majority of tissue repair and growth hormone secretion occurs during deep sleep stages. 7–9 hours of quality sleep per night supports the biological environment in which recovery peptides operate.
03
Activity balance. Avoid complete immobilization (which impedes collagen remodeling) and overuse (which re-injures tissue). Progressive loading appropriate to the injury stage supports functional recovery.
04
Stress management. Elevated cortisol chronically impairs immune function and tissue repair. Evidence-based stress reduction techniques support the recovery environment.
Injection Technique
Standard subcutaneous injection guidance from clinical best-practice references.
01
Wash hands thoroughly. Clean your work surface. Gather all supplies before beginning.
02
Wipe the vial rubber stopper with a fresh alcohol swab. Allow it to dry completely before inserting a needle.
03
Draw the calculated dose volume into a sterile insulin syringe. Invert the syringe and tap to remove air bubbles; expel them before withdrawing the needle from the vial.
04
Select an injection site: abdomen (at least 2 inches from the navel), outer thigh, or upper outer arm. Clean with a fresh alcohol swab and allow to dry.
05
Pinch a fold of skin between thumb and forefinger. Insert the needle at a 45–90° angle depending on body fat thickness -45° for leaner individuals, 90° for more subcutaneous tissue.
06
Do not aspirate. Current clinical guidelines do not recommend aspiration for subcutaneous injections. Inject slowly and steadily over 2–3 seconds.
07
Wait 3–5 seconds after the plunger bottoms out before withdrawing the needle at the same angle. Apply gentle pressure with a clean swab -do not rub vigorously.
08
Rotate injection sites systematically with every dose. Reusing the same site repeatedly causes lipohypertrophy (hardened fat tissue) which reduces absorption consistency.
09
Dispose of used needles and syringes immediately in a puncture-resistant sharps container. Never recap needles by hand.
Important Notes
⚠
Research use only. PNC-27 is not FDA-approved for human use. Human clinical data may be limited. Do not use without consulting a qualified healthcare professional.
◎
One syringe per injection. Never reuse needles or syringes. Each injection requires a fresh, sterile syringe to prevent contamination and infection risk.
⚠
IV route only -research protocol-dependent dosing
⚠
Very early-stage research compound
◎
Document your protocol. Record daily dose, injection site, and any observations. This supports consistency and allows you to identify patterns or issues over the course of the cycle.
◎
Inspect before each use. The reconstituted solution should be clear and colorless. Discard if cloudy, discolored, or if particulates are visible.
References
All dosing recommendations and mechanism descriptions on this page are derived from the following peer-reviewed publications and regulatory documents.
1
PubMed 20080680
Sarafraz-Yazdi E et al. Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and kills cancer cells by binding to HDM-2 in their membranes
pubmed.ncbi.nlm.nih.gov/20080680 ↗
2
PubMed 25117093
Davitt K et al. The anti-cancer peptide PNC-27 induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line
pubmed.ncbi.nlm.nih.gov/25117093 ↗
